(Q43488442)

23 November 2017

Survival of patients with severe congestive heart failure treated with oral milrinone (English)

1 reference

23 November 2017

congestive heart failure

1 reference

D S Baim

1

1 reference

23 November 2017

W S Colucci

2

1 reference

23 November 2017

E S Monrad

3

1 reference

23 November 2017

H S Smith

4

1 reference

23 November 2017

R F Wright

5

1 reference

23 November 2017

A Lanoue

6

1 reference

23 November 2017

D F Gauthier

7

1 reference

23 November 2017

B J Ransil

8

1 reference

23 November 2017

W Grossman

9

1 reference

23 November 2017

E Braunwald

10

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 March 1986

1 reference

Journal of the American College of Cardiology

23 November 2017

1 reference

23 November 2017

7

1 reference

23 November 2017

3

1 reference

23 November 2017

661-670

1 reference

Evaluating the efficacy of new inotropic agents

23 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

The Natural History of Congestive Heart Failure: The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Determinants of clinical response and survival in patients with congestive heart failure treated with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Results of long-term vasodilator therapy in patients with refractory congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

The natural history of idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Factors influencing the one-year mortality of dilated cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Effect of vasodilators on survival in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

A new inotropic drug: its promise and a caution

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Should the failing heart be stimulated?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Acute dose range study of milrinone in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

High prevalence of nonsustained ventricular tachycardia in severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

The effects of milrinone on conduction, reflection, and automaticity in canine Purkinje fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

Electrophysiologic effects of milrinone in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980478-8

7 January 2021

10.1016/S0735-1097(86)80478-8

Identifiers

DOI

1 reference

23 November 2017

1 reference